’% Dr Habcebullaha Life Sciences

To,Date: 11.02.2019

1) BSE Limited

PJ. Towers, Dale! Street,

Mumbai —400 001

2) Metropolitan Stock Exchange of India Limited

Vibgyor Towers, 4th floor, Plot No. C62, Opp. Trident Hotel,

Sandra Kurla Complex, Sandra (E), Mumbai— 400 098

3) Ahmedabad Stock Exchange Limited

Kamdhenu Complex, Opp. Sahajanand College,

Panjara Poie, Ambawadi, Ahmedabad —380 015

Dear Sir/Madam,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) (c) of SEBi (Listing Obligations and

Disclosure requirements) regulations, 2015

Unit: Dr Habeebullah Life Sciences Limited — (Scrip Code: 539267)

With reference to the subject cited, this is to inform the Exchange that meeting of the board of directors of

M/S. DR HABEEBULLAH LlFE SClENCES LIMITED held on Monday, the 11th day of February, 2019 at 3.30

pm. at the registered office of the company the following were duly considered and approved by the

Board;

Un—audited financial results for the Quarter ended 31.12.2018.

Limited Review Report for the quarter ended 31.12.2018

3. in view of expioring various opportunities for the allrround growth of the company and emerging

opportunities in healthcare sedor, the Company proposed to incorporate a wholly owned

subsidiary of M/s. Dr Habeebullah Life Sciences Limited, in the name & Style of M/s. Krisani

Genomics Private Limited or such other name as may be approved by the registrar of companies,

Hyderabad.

Un—audited standalone financial results along with Limited Review Report will be uploaded on

company’s website www.drhlsl.com

Furthermore, an extract of the aforesaid Financial Results shall be published in the manner as

prescribed under SEBi (LODR) Regulations, 2015.

The meeting of the Board of Directors commenced at 3.30 PM (lST) and concluded at 5.00 PM (lST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For DR HABEEBULLAH LlFE

“1;”K. Krishnam Raju

Dr Habccbullah Life Sciences Ltd(Formerly Known as PC Products India Limited)

Rmrri.()fi' : 7.5"“. iinimwl \ lx‘nmk‘ i’nnw'mfllx iéziii‘nilm \n ninl ll\ :ilmii .. Qliiifié-ifs’ 35% in:

PART-I

In: In unisSTANDALONE UNAUDITED FINANCIAL RESULTS FOR 1HE QUARTER III AND 9 MONTHS ENDED 3151' DECEMBER. 2018

PlrtiwllriQuenren ENDED 9 ended

i 3 Months ended {Corresponding 3 Proceeding 3 9 Months ended snows ended

s No :31424015 | months ended months ended 31-12-2018 31-12-2017'

. in previous year 30-09-2018

:__ _

3142-2011

_ _yLIdejtri _ yithvdited UnAudIted unAudned UnAudIudI Revenue from Oggfations

_

5f. 0!: 20.12 52.92 139.44 37.62II Other Income

_ j __

--

--

Ill Toni mildew __

456.05 20.12 52.92 139.44 37.52

IV ExamsCost of Material r

.

_

I _' 733'" h

1.31 4.96 13.31 1._s7__Purchase of Stock—in-trade_.. __ _

—-

-

Changes in inventories of finished goods. Work In ~-

--

grggrg; and Stock in trade 1 _ _- _~-

-

Em I no benefits ex ense_

1 30£2_ 19.25_ 31.29 96.17 59.26Finance Costs

__ __ _

--

--

reciatlon and Amorusatlon expense__

_f ___9,[}9_

0.09 0.28 —

Professional Charges_

. 10.57 - N43 35.81 -

Other Ex enses .'”2.17

_ _

25.63 60.71 161.33 42.90total Expenses T

_ _ __....

102.13__

46.19 111.43 306.90 104.03V Profit/(Loss) from before Exceptional Items and tax

um_

__ (46.13} 125.07] (55.56] (167.46: 166.41)VI Ewe Iona! Items_

_

--

--

-

VII Prdfimlosfl before tax |V-VI1__ _._ 146.13} {26.07} [58.56] [151.46] [66.41]VIII Tax

'

r .

_

-»

-

Current Tax I -

-

Muted Tax_ ___ J _ _

--

-

III rIuIIlf (1.1m) IUI mt! wIIUII Irom LonlIIIIIlngand.“ VII-VIII

_ ___

j_ (“_JJL (26.07} [58.561 (161.45} (66.41)x Pram (Lou: lrum discontinuing operations

L "___ _

_

_

fl _

_

..

II ‘III E-pense of discontinuing operationsT

,_

__

)III Profit] (Loss) for the period Irorn diSCDHlI'fl—L‘II-nfl'

_

operations utter tau lx-XI)_

_.

.

XIII Prof-1.! {Loss} lor the period Illmll_ _1 (35.13) _Lzaovi {58.56} {167.46} [66.41]XIV Other Comprehensive Income I

A) (I) Items that will not he reclassified to profit or

loss

(i) Income Tax related to items that will not be

relclassified to profit or loss

BI (I) Items that will he reclasslled to profit or loss

(ii) Income Tau relating to items that will be

XV Total Comprehensive Income for the period

— _ h — _

leIIele) (Comprising Profit (loss) and Other

Cownhensive Income for the Perm _

-__,.____ {46.131 __ _1;6_.0_7L __ [58.56 (167.46} (66.41]XVI Earnings Per Equity Share (For ContinuingOperations) (Face Value INR 10/- each)

1) Basic[0.38) (0.23) (0.49) (1.40) (0.60)2) Diluted

_ _10.32: 10.23} {0.40: {1.151 10.60XVII Earnings Per Equity Share (For Discontinued

Operations) [Face Value INR 10/- each)

1) Basic

2) Diluted|

‘_

_

XVIII Earnlngs Per Equity Share (For Continued and Ir

Discontinued OperationsMFace Value INR 10/-

each]

1) Basic_

_ __ _ @g1+_ I013! (01191 11.40] 10.60)2) Diluted

‘ ._._.. -._, £9.12] _ p.231 _ I040} 11.151 Ill-60XIX Paid Up Equity Share Capital (Face Value of ink 10/.

mm}_

__ I.2_21.3_7 1105.87 1,221.37 1,221.37 1105.87XX Reserves excluding Revaluation Reserves

as per balance sheet oI previous

madam _ 4155.39 _ I190.07| mus] 1142.23] (190.07:

em:

1The Unaudited Standalone financial results for the Quarter Ill and 9 months period ended 31, December 2018 were reviewed and recommended bythe Audit Committee and approved by the Board oi DIM‘IJDIS at irs meeting held on February 11. 2019. The Statutory Auditors have nrried out

the Limited Review of the Unaudited Standalone irnancml Results in accordant e with Regulation 33 of SEBI (LODR) Regulations, 2015).

2The Unaudited standalone financial results at the (.ompany have been prepared in accordance with the recognition and measurement principleslaid down in Indian Accounting Standard» ilNiJ AS) 3-1 Interim financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the

Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and

Exchange Board of lndIa["SEBl"l and Regulation J3 ol Slllll (lODlt) Regulatlons. 2015 amd SEBl Circular dated 05th July, 2016.

3 Adoption of lnd AS 115 - Revenue lrom (unit-ms Wlll'l tusttimets

Effective April 1. 2018. the Company has adopted Ind AS 11'; “Revenue from ( ontracts with Customers" using the cumulative catch-up transition

method which is applied to contracts that were not completed as of April 1, 2018. Accordingly. the comparatives have not been retrospectivelyadjusted. The efiect an adoption 0' ind AS 115 was Insignificant on the linanuul statements.

4 The Company has only one reportable segment as per requirements 01 AS 108 “Operating Segments" i.e., Health Care Sector. Hence, the separatedisclosure on Segment information is not required

5 The figures oi the corresponding previous period have been regrouped/reclastihed wherever necessary. to make them comparable.

6 The results are also available on the webrste oi lht‘ tompanv www drhlslxom

Place : Hyderabad For DR HABEEBULLAH UFE SCIENCDate : 11/02/2019

K. Krishnam Raju

Executive Chairman (DIN 0087

DR HABEEBULLAH LIFE SCIENCES LIMITED

(Formerly known as PC PRODUCTS INDIA LIMITED)Regd. Office: 2-5-36/CLRD/1, 5y No. 36, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandel, Hyderabad - 500 048, Telangana State, India

Contact No. 040-2970 3333.491 90300 57370 E-mail Id: IMOQdI‘hIsI.C0mCIN No : L85110T61996PLC099198 Webslte : www.drhlsl.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED

315T DECEMBER, 2013

Rupees in LacsParticulars

QUARTER ENDED Year to Date

3 Months ended Correspondin Preceeding 3 Year to date for Year to date for

31-12-2018 g 3 months months ended the Current the Previous yearended In 30—09-2018 period ended 31- ended 31—12-2017

previous year 12-2018

31-12-2017

_ ___ _

UnAudited UnAudited UnAudited UnAudited UnAudltedTotal income from operations (net) 56.05 20.12 52.92 139.44 37.62Net Profit / (Loss) for the period (before Tax, Exceptional

and £9.- Extraordinary: items ] (46.13) (26.07) (58.56) (167.46) (66.41)Net Profit / (Loss) for the period before tax (after Exceptionaland/or Extraordinary items 1.

_ _ __ __

(46.13) (26.07) (58.56) (167.46) (66.41)Net Profit/ (Loss) for the period after tax (after Exceptional

andfigi Extraordinary items 1. _

(46-13) (25-07) (58-55) (167.45) (55-41)Total Comprehensive Income for the period [Comprising Profit

/ (Loss) for the period (after tax) and Other Comprehensive ;-

--

WE! taxi)__

Equity Share Capital (Face Value INR 10/- each) ) 1,221.37 1105.87 1,221.37 1,221.37 1,105.87Earnings Per Share (for continuing and discontinued

+

omratigng (of INR 101- each)____

Basic_ m

(0.38) (0.23) (0.49) (1.40) (0.60)Diluted

___‘

(0.32) (0.23) (0.40) (1.15) (0.60)

was:

1. The Unaudited Standalone financial results for the Quarter Ill and 9 months period ended 31, December 2018 were reviewed and recommended bythe Audit Committee and approved by the Board of Directors at its meeting held on February 11, 2019. The Statutory Auditors have carried out theLimited Review of the Unaudited Standalone l-inancial Results in accordance with Regulation 33 of SEBl (LODR) Regulations, 2015).2. The Unaudited standalone financial results oi the Company have been prepared in accordance with the recognition and measurement principles laiddown In Indian Accounting Standards (IND AS) 34 interim i‘rnanciui Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") readwith relevant rules issued thereunder, other accounting principles. generally accepted in India and guidelines issued by Securities and Exchange Board oflndia("SEBl") and Regulation 33 of SEBl (LODR) Regulations, 2015 amd SEBI Circular dated 05th July, 2016.

3. The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" l.e., Health Care Sector. Hence, the separatedisclosure on Segment information is not required.

4. The figures of the corresponding previous period have been regrouped/ieclassified wherever necessary, to make them comparable.5. The above is an extract of the detailed format ol the Standalone Statement of Unaudited Financial Resluts filed with the Stock Exchanges under Reg.33 of SEBI (LODR) Regulations, 2015. The Compll‘lt‘ Financial Results are available on the Websites of BSE Limited (www.bseindia.com), MSEl Limited(www.mcx-scx.com), ASE Limited (www.aseliridr.i.mm) and on the Company's Website www.drhlsl.com

Place : Hyderabad,- :42“ For on HABEEBULLAl-I use some

. "A380V ““0

Date . 11/02/2019 43 7

0,1 g c

°a/_x 1‘“ . wsm.

( *(Hyderabad) * I) K.Krishnam Raju

0 a, fl_

_

Executive Chairman (DIN 0087

\xaMs_

'

\(gdAct-.0“

1101 /B, Manjeera Trinity Corporate,

JNTU-Hitech City Road, Kukatpally,

Hyderabad-500072, Telangana, INDIA

Tel: +91 40 6814 2999

8° Associates

Chartered AccountantsLimited Review Report

Review Report to

The Board of Directors

DR HABEEBULLAH LIFE SCIENCES LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of DR

HABEEBULLAH LIFE SCIENCES LIMITED (‘the Company’) for the quarter ended 31St December, 2018 and

the year to-date results for the period 1St April 2018 to 31St December, 2018, (the Statement), beingsubmitted by the Company pursuant to the requirements of Regulation 33 as modified by Circular No.

CIR/CFD/FAC/62/2016 dated July 5, 2016 and Regulation 52 as modified by Circular No.

CIR/IMD/DF1/69/2016 dated August 10, 2016 read with Regulation 63(2) of the Securities and ExchangeBoard of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).This Statement, which is the responsibility of the Company's Management and has been approved bythe Board of Directors, has been prepared in accordance with Ind AS 34 ‘Interim Financial Reporting’,prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder

and other recognized accounting practices and policies generally accepted in India. Our responsibility is

to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review

of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the

Institute of Chartered Accountants of India. This standard requires that we plan and perform the

review to obtain moderate assurance as to whether the Statement is free of material misstatement. A

review is limited primarily to inquiries of Company personnel and analytical procedures applied to

financial data and thus provide less assurance than an audit. We have not performed an audit and

accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe

that the accompanying Statement of unaudited standalone financial results and financial position which

are prepared in accordance with Ind AS 34, prescribed under Section 133 of the Companies Act, 2013

read with relevant rules issued thereunder and other recognized accounting practices and policies has

not disclosed the information required to be disclosed in terms of the Listing Regulations including the

manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

ofiwxaa.Ananthakrishnan G

Partner"

.

Membership No.1205226 4-..

Place: HyderabadDate: 11‘h February 2019

Head Office: Floor 3, Enterprise Centre, Nehru Road, Near Domestic Airport, Vile Parle (E), Mumbai 400099, INDIA, Tel: +91 22 3358 9800

Ahmedabadl Bengaluru | Chennai [Hyderabad | Kochi | Kolkata | Mumbai | New Delhi-Gurugram l Pune www.mska.in